ACM
ARQT icon

Aster Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Aster Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-235
Closed -$3.22K – 1032
2025
Q1 		$3.22K Sell
235
-170
-42% -$2.4K ﹤0.01% 1152
2024
Q4 		$5.64K Buy
+405
New +$4.44K ﹤0.01% 840

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Aster Capital Management's ARQT Position: Q2 2025 in Review

Aster Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 235 shares — an estimated $3.22K sold.

Aster Capital Management first reported a position in ARQT in Q4 2024 and held it in 2 quarters. The position peaked at $5.64K in Q4 2024. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

  • Aster Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Aster Capital Management sold 235 Arcutis Biotherapeutics shares in Q2 2025, an estimated $3.22K.
  • Aster Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 2 quarters.
  • Aster Capital Management's Arcutis Biotherapeutics position peaked at $5.64K in Q4 2024.
  • 230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on Aster Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.